Sign in
CLCS Stock Price, Chart, Stats & News
Cell Source, Inc.
Save
Cell Source, Inc. (CLCS) does not currently pay a dividend.
40.76M
Market cap
–
Current P/E
–
Forward P/E
CLCS chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma.
Similar securities
Based on sector and market capitalization
Report issue